Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Kala Pharmaceuticals (KALA) Misses Q3 EPS by 6c, Revenues Beat
November 5, 2020 8:43 AM ESTKala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($0.50), $0.06 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.22 million versus the consensus estimate of $2.01 million.
We are pleased with our third quarter results and the fourth quarter of 2020... More
